Hemostemix Stock Forecast, Price & News

+0.01 (+2.17 %)
(As of 07/27/2021 03:41 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume42,004 shs
Average Volume159,031 shs
Market CapitalizationC$13.51 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive HEM News and Ratings via Email

Sign-up to receive the latest news and ratings for Hemostemix and its competitors with MarketBeat's FREE daily newsletter.

About Hemostemix

Hemostemix Inc., a biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. It develops cell therapy products from the patient's own blood, a relatively non-invasive source of therapeutic cells. The company's lead product is ACP-01, an autologous cell therapy for the treatment of critical limb ischemia, which is in Phase II clinical trial in Canada and the United States. It is also developing various types of cell products, such as synergetic cell populations and neural cell precursors. The company is headquartered in Calgary, Canada.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.72 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Hemostemix (CVE:HEM) Frequently Asked Questions

What stocks does MarketBeat like better than Hemostemix?

Wall Street analysts have given Hemostemix a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Hemostemix wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has Hemostemix's stock been impacted by COVID-19?

Hemostemix's stock was trading at C$0.02 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, HEM shares have increased by 1,466.7% and is now trading at C$0.24.
View which stocks have been most impacted by COVID-19

Who are Hemostemix's key executives?

Hemostemix's management team includes the following people:
  • Mr. Thomas A. Smeenk B.A., BA Hons, Co-Founder, Pres, CEO & Director (Age 59, Pay $277.08k)
  • Ms. Christina Wu CPA, Interim Chief Financial Officer
  • Ms. Eilat Bain, Director of Operations

Who are some of Hemostemix's key competitors?

What other stocks do shareholders of Hemostemix own?

What is Hemostemix's stock symbol?

Hemostemix trades on the Canadian Venture Exchange (CVE) under the ticker symbol "HEM."

How do I buy shares of Hemostemix?

Shares of HEM and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Hemostemix's stock price today?

One share of HEM stock can currently be purchased for approximately C$0.24.

How much money does Hemostemix make?

Hemostemix has a market capitalization of C$13.51 million.

What is Hemostemix's official website?

The official website for Hemostemix is

Where are Hemostemix's headquarters?

Hemostemix is headquartered at Bay 1, PO Box 10, BLACKFALDS, AB T0M 0J0, Canada.

How can I contact Hemostemix?

Hemostemix's mailing address is Bay 1, PO Box 10, BLACKFALDS, AB T0M 0J0, Canada. The biotechnology company can be reached via phone at +1-403-3409207.

This page was last updated on 7/28/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.